A promising strategy change for the pharmaceutical Biovail

Home » Media Mentions » A promising strategy change for the pharmaceutical Biovail

April 4, 2009

The revival of the pharmaceutical company Biovail (Tor., BVF, $ 13.07) is on track and could offer a good investment opportunity, according to some financial.

Read this French article on Les Affaires…

Claret

Author

Claret
Claret Asset Management specializes in offering portfolio management services to high net worth clients. We are completely independent and free of conflicts of interest. Claret was founded in 1996 with the objective of answering the growing needs of private investors.

You may also enjoy:

How Are the Markets Doing?

What are REITs? Real Estate Investment Trusts, Explained

P/E Ratio: Price-to-Earnings Ratio Explained

3 Trading Order Types Explained

Should We Rethink the 4% Rule? Debunking Dave Ramsey